netilmicin

Trade name: netromycin

Small moleculeapproved

Approved

Feb 28, 1983

Netilmicin is a semisynthetic, water soluble antibiotic of the aminoglycoside group, produced by the fermentation of Micromonospora inyoensis, a species of actinomycete. Aminoglycosides are useful primarily in infections involving aerobic, Gram-negative bacteria, such as Pseudomonas, Acinetobacter, and Enterobacter. It is active at low concentrations against a wide variety of pathogenic bacteria including Escherichia coli, bacteria of the Klebsiella-Enterobacter-Serratia group, Citrobacter sp., Proteus sp. (indole-positive and indole-negative), including Proteus mirabilis, P. morganii, P. rettgrei, P. vulgaris, Pseudomonas aeruginosa and Neisseria gonorrhoea. Netilmicin is also active in vitro against isolates of Hemophilus influenzae, Salmonella sp., Shigella sp. and against penicillinase and non-penicillinase-producing Staphylococcus including methicillin-resistant strains. Some strains of Providencia sp., Acinetobacter sp. and Aeromonas sp. are also sensitive to netilmicin. Many strains of the above organisms which are found to be resistant to other aminoglycosides, such as kanamycin, gentamicin, tobramycin and sisomicin, are susceptible to netilmicin in vitro. Occasionally, strains have been identified which are resistant to amikacin but susceptible to netilmicin. The combination of netilmicin and penicillin G has a synergistic bactericidal effect against most strains of Streptococcus faecalis (enterococcus). The combined effect of netilmicin and carbenicillin or ticarcillin is synergistic for many strains of Pseudomonas aeruginosa. In addition, many isolates of Serratia, which are resistant to multiple antibiotics, are inhibited by synergistic combinations of netilmicin with carbenicillin, azlocillin, mezlocillin, cefamandole, cefotaxime or moxalactam. Netilmicin "irreversibly" binds to specific 30S-subunit proteins and 16S rRNA. Specifically netilmicin binds to four nucleotides of 16S rRNA and a single amino acid of protein S12. This interferes with decoding site in the vicinity of nucleotide 1400 in 16S rRNA of 30S subunit. This region interacts with the wobble base in the anticodon of tRNA. This leads to interference with the initiation complex, misreading of mRNA so incorrect amino acids are inserted into the polypeptide leading to nonfunctional or toxic peptides and the breakup of polysomes into nonfunctional monosomes, leaving the bacterium unable to synthesize proteins vital to its growth. — NCATS

Clinical trial activity

2 trials · 5 clinical orgs · 2 marketing orgs

Phase 1
0
Phase 2
0
Phase 3
0
Phase 4
2

Earliest trial started Jan 1, 1998 (NCT01559753)

Timeline

1980s

  1. Feb 28, 1983

    Schering — Earliest FDA Approval

  2. Feb 28, 1983

    Schering — NDA Organization

  3. Feb 28, 1983

    Schering — NDA Secondary Org

  4. Feb 28, 1983

    Schering-Plough — NDA Secondary Org

Indications

Mechanism of action

Approval history

  • approvedFeb 28, 1983

Chemistry & pharmacology

Loading structure…

SMILES

CCN[C@@H]1C[C@H](N)[C@@H](O[C@H]2OC(CN)=CC[C@H]2N)[C@H](O)[C@H]1O[C@H]1OC[C@](C)(O)[C@H](NC)[C@H]1O.CCN[C@@H]1C[C@H](N)[C@@H](O[C@H]2OC(CN)=CC[C@H]2N)[C@H](O)[C@H]1O[C@H]1OC[C@](C)(O)[C@H](NC)[C@H]1O.O=S(=O)(O)O.O=S(=O)(O)O.O=S(=O)(O)O.O=S(=O)(O)O.O=S(=O)(O)O
Mol. weight
1441.57 g/mol
Lipinski Ro5
2 violation(s)
Rule of 3
No
Chirality
Single Stereoisomer
Inorganic
No
Polymer
No
Delivery
Parenteral
Availability
Discontinued

Oral

No

Parenteral

Yes

Topical

No

Sources

Also known as

  • 1-n-ethylsisomicin
  • 1-n-ethylsisomicin
  • netillin
  • netillin
  • netilmicin
  • netilmicin
  • netilmicin
  • netilmicin
  • netilmicin
  • netilmicin
  • netilmicin
  • netilmicin sulfate
  • netilmicin sulfate
  • netilmicin sulfate
  • netilmicin sulfate
  • netilmicin sulfate
  • netilmicin sulfate
  • netilmicin sulfate
  • netilmycin
  • netilmycin
  • netilmycin
  • netromycin
  • netromycin
  • netromycin
  • netromycin
  • sch-20569
  • sch-20569

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT06404541Phase 4Jan 10, 2024Cairo University
NCT01559753Phase 4Jan 1, 1998French Society for Intensive Care, GlaxoSmithKline, SmithKline Beecham, University of Franche-Comté
Showing 2 of 2 trials
Page 1 / 1

Organizations

Research & Development (5)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Cairo UniversityAcademic/Hospital1112024
French Society for Intensive CareAcademic/Hospital1011998
GlaxoSmithKlineFor profit1011998
SmithKline BeechamFor profit1011998
University of Franche-ComtéAcademic/Hospital1111998
5 organizations
Page 1 / 1

Marketing (3)

OrganizationOrg typeRelationshipDate
ScheringFor profitNDAFeb 28, 1983
ScheringFor profitNDA2Feb 28, 1983
Schering-PloughFor profitNDA2Feb 28, 1983